

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM439005

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Kodiak Sciences Inc.		08/11/2017	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Baker Bros. Advisors LP		
Street Address:	667 Madison Avenue, 21st Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10065		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	86772416	KODIAK SCIENCES	
Serial Number:	86772436	KODIAK	
Serial Number:	86772441	KODIAK PHARMACEUTICALS	
CORRESPONDENCE DATA			
Fax Number:	9494754754		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	949-451-3800		
Email:	skann@gibsondunn.com		
Correspondent Name:	Stephanie Kann		
Address Line 1:	3161 Michelson Drive		
Address Line 2:	Gibson, Dunn & Crutcher LLP		
Address Line 4:	Irvine, CALIFORNIA 92612		
ATTORNEY DOCKET NUMBER:	12742-00005		
NAME OF SUBMITTER:	Stephanie Kann		
SIGNATURE:	/stephanie kann/		
DATE SIGNED:	08/11/2017		
Total Attachments: 13			
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page1.tif			
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page2.tif			

CH \$90.00 86772416

source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page3.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page4.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page5.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page6.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page7.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page8.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page9.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page10.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page11.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page12.tif
source=Kodiak Sciences - IPSA (Kodiak Sciences Inc) - Executed#page13.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of August 11, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified or replaced from time to time, this “IP Security Agreement”), is made by Kodiak Sciences Inc., a Delaware corporation (“Grantor”), in favor of Baker Bros. Advisors LP, a Delaware limited partnership, as collateral agent for the Purchasers (as defined in the Note Purchase Agreement referred to below) (in such capacity, together with its successors and permitted assigns, “Designated Agent”).

WHEREAS, Grantor issued Notes (as such term is defined in the Note Purchase Agreement (as hereinafter defined)) pursuant to that certain Convertible Note Purchase and Security Agreement, dated as of August 11, 2017 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”), by and among Kodiak Sciences Inc., a Delaware corporation (the “Company”), the Grantor and the other guarantors from time to time party thereto, the purchasers from time to time party thereto (each a “Purchaser” and collectively, the “Purchasers”) and the Designated Agent, pursuant to which Grantor granted a security interest to Designated Agent, for the benefit of the Purchasers, in, among other things, the IP Collateral (as defined below) of Grantor;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Grantor hereby agrees with Designated Agent as follows:

SECTION 1. Defined Terms

Unless otherwise defined herein, terms defined in the Note Purchase Agreement and used herein have the meaning given to them in the Note Purchase Agreement.

SECTION 2. Grant of Security Interest in IP Collateral

Grantor hereby grants to Designated Agent, for the ratable benefit of the Purchasers, a continuing security interest in all of Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired, and wherever located (the “IP Collateral”), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of Grantor’s obligations under the Note Purchase Agreement:

(a) (i) all United States and foreign copyrights, whether or not the underlying works of authorship have been published and whether as author, assignee, transferee or otherwise, including but not limited to copyrights in software and databases, all Mask Works (as defined in 17 U.S.C. § 901 of the U.S. Copyright Act) and all works of authorship, all right, title and interest to make and exploit all derivative works based on or adopted from works covered by such copyrights, and all copyright registrations, copyright applications, mask works registrations and mask works applications, and any renewals or extensions thereof, including each registration and application identified in Schedule A, and (ii) the rights to print, publish and distribute any of the foregoing (“Copyrights”);

(b) all Copyright licenses to the extent Grantor is not the granting party, including any of the foregoing identified in Schedule A;

(c) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (a) and (b) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (a) and (b) above;

(d) (i) all United States, state and foreign trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade dress, trade styles, logos, or other indicia of origin or source identification, Internet domain names, trademark and service mark registrations, designs and general intangibles of like nature and applications for trademark or service mark registrations and any renewals thereof, including each registration and application identified in Schedule B (but excluding in all cases all intent-to-use United States trademark applications for which an amendment to allege use or statement of use has not been filed under 15 U.S.C. § 1051(c) or 15 U.S.C. § 1051(d), respectively, or if filed, has not been deemed in conformance with 15 U.S.C. § 1051(a) or examined and accepted, respectively, by the U.S. Patent and Trademark Office provided that upon such filing and acceptance, such intent-to-use applications shall be included in the definition of Trademarks) and (ii) the goodwill of the business connected with the use of, and symbolized by, each of the above (collectively, the "Trademarks");

(e) all Trademark licenses to the extent Grantor is not the granting party, including any of the foregoing identified in Schedule B;

(f) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (d) and (e) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (d) and (e) above;

(g) (i) all United States and foreign patents, patent applications and patentable inventions, including each issued patent and patent application identified in Schedule C, all certificates of invention or similar property rights and all registrations, recordings and pending applications thereof, (ii) all inventions and improvements described and claimed therein and (iii) all reissues, divisions, reexaminations, continuations, continuations-in-part, substitutes, renewals, and extensions thereof, all improvements thereon (collectively, the "Patents");

(h) all Patent licenses to the extent Grantor is not the granting party, including any of the foregoing identified in Schedule C;

(i) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (g) and (h) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (g) and (h) above; and

(j) all books and records relating to any of the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments,

accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

SECTION 3. Recordation

Grantor authorizes and requests that the Commissioner of Patents and Trademarks and any other applicable United States or foreign government officer record this IP Security Agreement.

SECTION 4. Execution in Counterparts

This IP Security Agreement may be executed in any number of counterparts (including by telecopy or other electronic transmission), each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Governing Law

THIS IP SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

SECTION 6. Conflict Provision


This IP Security Agreement has been entered into in conjunction with the provisions of the Note Purchase Agreement. The rights and remedies of each party hereto with respect to the security interest granted herein are without prejudice to, and are in addition to those set forth in the Note Purchase Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this IP Security Agreement are in conflict with the Note Purchase Agreement, the provisions of the Note Purchase Agreement, as applicable, shall govern.

[Signature pages follow]

IN WITNESS WHEREOF, each of the undersigned has caused this IP Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:

KODIAK SCIENCES INC.

By: 
Name: Victor Perloth, M.D.
Title: Chairman and CEO

DESIGNATED AGENT:

BAKER BROS. ADVISORS LP,
a Delaware limited partnership

By: _____
Name:
Title:

[Signature Page to IP Security Agreement]

IN WITNESS WHEREOF, each of the undersigned has caused this IP Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:

KODIAK SCIENCES INC.

By: _____

Name: Victor Perloth, M.D.

Title: Chairman and CEO

DESIGNATED AGENT:

BAKER BROS. ADVISORS LP,

a Delaware limited partnership

By: _____

Name: Scott Lessing

Title: President

COPYRIGHTS

None.

TRADEMARKS

[To be attached.]

CaseNumber	Country	TrademarkName	TrademarkStatus	Class	ApplNumber	FileDate	RegNumber	RegDate	NextRenewalDate	PubNumber	PubDate
KODIAK.011T	US	KODIAK SCIENCES	Allowed	01 Int., 05 Int., 42 Int.	86/772416	29-Sep-2015					03-May-2016
KODIAK.015WCA	CA	KODIAK	Pending	01 Int., 05 Int., 42 Int.	1755525	18-Nov-2015					01-Feb-2016
KODIAK.017WCH	CH	KODIAK	Registered	01 Int., 05 Int., 42 Int.	64541/2015	19-Nov-2015	683408	01-Feb-2016	19-Nov-2025		27-Dec-2016
KODIAK.018WCN	CN	KODIAK	Published	01 Int.	18511416	04-Dec-2015					27-Dec-2016
KODIAK.019WCN	CN	KODIAK	Published	05 Int.	18511415	04-Dec-2015					27-Dec-2016
KODIAK.020WCN	CN	KODIAK	Registered	42 Int.	18511417	04-Dec-2015	18511417	28-Mar-2017	27-Mar-2027		27-Dec-2016
KODIAK.021WCN	CN	KODIAK in Chinese Characters	Registered	01 Int.	18550352	09-Dec-2015	18550352	21-Jan-2017	20-Jan-2027		20-Oct-2016
KODIAK.022WCN	CN	KODIAK in Chinese Characters	Registered	05 Int.	18550353	09-Dec-2015	18550353	21-Jan-2017	20-Jan-2027		20-Oct-2016
KODIAK.023WCN	CN	KODIAK in Chinese Characters	Registered	42 Int.	18550354	09-Dec-2015	18550354	28-Mar-2017	27-Mar-2027		27-Dec-2016
KODIAK.024WEM	EM	KODIAK	Registered	01 Int., 05 Int., 42 Int.	014808448	19-Nov-2015	014808448	17-Mar-2016	19-Nov-2025		09-Dec-2015
KODIAK.025WJP	JP	KODIAK	Registered	01 Int., 05 Int., 42 Int.	2015-114422	20-Nov-2015	5844013	22-Apr-2016	22-Apr-2026		08-Dec-2015
KODIAK.026WSG	SG	KODIAK	Registered	01 Int., 05 Int., 42 Int.	40201521514U	07-Dec-2015	40201521514U	07-Dec-2015	07-Dec-2025		26-Feb-2016
KODIAK.029T	US	KODIAK	Allowed	01 Int., 05 Int., 42 Int.	86/772436	29-Sep-2015					01-Mar-2016
KODIAK.030T	US	KODIAK PHARMACEUTICALS	Allowed	01 Int., 05 Int., 42 Int.	86/772441	29-Sep-2015					03-May-2016
KODIAK.037WCN	CN	KODIAK in New Chinese Characters	Unfiled	01 Int., 05 Int., 42 Int.							

PATENTS

[To be attached.]

Kodiak Sciences - Patent Status Report

8/3/2017

Case No.	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	PubNumber:	PubDate:	Expiration Date:
KDIAK.001PR	COMPLEMENT FACTOR D ANTIBODIES AND CONJUGATES THEREOF	US	Pending	62/485718	4/14/2017					4/14/2018
KDIAK.004A	ANTIBODIES AND CONJUGATES THEREOF	US	Published	15/394500	12/29/2016			2017/0190766 A1	7/6/2017	
KDIAK.004WO	ANTIBODIES AND CONJUGATES THEREOF	WO	Published	PCT/US2016/069336	12/29/2016			WO 2017/117464	7/6/2017	8/30/2018
KDIAK.005C1	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	US	Issued	13/959563	8/5/2013	8846021	9/30/2014	2013/0337534 A1	12/19/2013	8/28/2028
KDIAK.005C2	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	US	Published	14/456875	8/11/2014			2015/0050714 A1	2/19/2015	
KDIAK.005EP	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	EP	Published	7752096.3	8/27/2008			1988910	12/11/2008	
KDIAK.005EPD1	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	EP	Pending	17165316.5	4/6/2017					
KDIAK.005JP	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	JP	Issued	2008-557399	8/28/2008	5528710	4/25/2014			2/28/2027
KDIAK.005JPD1	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION	JP	Issued	2013-235314	11/13/2013	5745009	5/15/2015	2014-043456	3/13/2014	2/28/2027
KDIAK.006AU	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	AU	Issued	2010330727	6/22/2012	2010330727	12/20/2010	2010330727	7/19/2012	12/20/2030
KDIAK.006BE1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	BE	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006BR	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	BR	Published	BR 11 2012 0145568	6/15/2012				3/14/2017	
KDIAK.006C2	TARGETED PHOSPHORYLCHOLINE POLYMER CONJUGATES	US	Published	15/182278	6/14/2016			2017/0007710 A1	1/12/2017	
KDIAK.006CA	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	CA	Pending	2783615	6/7/2012					
KDIAK.006CH1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	CH	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006CN	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	CN	Published	201080062252.70	12/20/2010			CN 102811713 A	12/5/2012	
KDIAK.006CND1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	CN	Published	201610439969.80	6/17/2016			CN 106075466 A	11/9/2016	
KDIAK.006DE1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	DE	Published	10838353	7/6/2012			2512462	10/24/2012	

Kodiak Sciences - Patent Status Report

8/3/2017

Case No.	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	PubNumber:	PubDate:	Expiration Date:
KDIAK.006DK1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	DK	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006EP1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	EP	Issued	10838353	7/6/2012	2512462	8/23/2017	2512462	10/24/2012	12/20/2030
KDIAK.006EP1D1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	EP	Pending	17181272	7/13/2017					
KDIAK.006FR1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	FR	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006GB1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	GB	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006IE1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	IE	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006IN	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	IN	Published	6116/CHENP/2012	7/12/2012				12/4/2015	
KDIAK.006IT1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	IT	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006JP1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	JP	Issued	2012-544945	6/18/2012	5760007	6/12/2015			12/20/2030
KDIAK.006JPD1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	JP	Issued	2015-115642	6/8/2015	5990629	8/19/2016	2016-14015	1/28/2016	12/20/2030
KDIAK.006JPD2	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	JP	Published	2016-159104	8/15/2016			2017-31410	2/9/2017	
KDIAK.006KR	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	KR	Published	10-2012-7018788	7/17/2012			10-2012-0123340	11/8/2010	
KDIAK.006LU1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	LU	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006MX	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	MX	Issued	MX/a/2012/006970	6/15/2012	346423	3/21/2017			12/20/2030
KDIAK.006MXD1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	MX	Pending	MX/a/2016/010818	8/19/2016					
KDIAK.006NL1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	NL	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006NP1	TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES	US	Issued	13/515913	8/27/2012	8765432	7/1/2014	2013/0034517 A1	2/7/2013	5/10/2030
KDIAK.006P1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	US	Published	15/099234	4/14/2016			2016/0287715 A1	6/10/2016	
KDIAK.006PT1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	PT	Published	10838353	7/6/2012			2512462	10/24/2012	
KDIAK.006SE1	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	SE	Published	10838353	7/6/2012			2512462	10/24/2012	

Kodiak Sciences - Patent Status Report

8/3/2017

Case No.	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	PubNumber:	PubDate:	Expiration Date:
KDIAK.006WO2	MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES	WO	Published	PCT/US2010/061358	12/20/2010			WO 2011/075736	6/23/2011	8/18/2012
KDIAK.007AU1	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	AU	Issued	2011239434	10/10/2012	2011239434	8/13/2015			4/15/2031
KDIAK.007AUD2	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	AU	Pending	2017201930	3/22/2017					
KDIAK.007BR	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	BR	Pending	BR 11 2012 0261185	10/11/2012					
KDIAK.007C2	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	US	Published	15/368376	12/2/2016			2017/0143841 A1	5/25/2017	
KDIAK.007CA	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	CA	Pending	2795667	10/4/2012					
KDIAK.007CND1	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	CN	Published	2.0161E+11	6/20/2016			CN 106432557A	2/22/2017	
KDIAK.007EP	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	EP	Published	11769715.1	11/9/2012			2558538	2/20/2013	
KDIAK.007IN	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	IN	Published	9473/CHENP/2012	11/7/2012				12/25/2015	
KDIAK.007JP1	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	JP	Published	2015-165282	8/24/2015			2016-40371	3/24/2016	
KDIAK.007KR	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	KR	Published	10-2012-7029878	11/14/2012			10-2013-0097636	9/3/2013	
KDIAK.007MX	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	MX	Pending	MX/a/2012/011876	10/12/2012					
KDIAK.007WO	HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS	WO	Published	PCT/US2011/032768	4/15/2011			WO 2011/130694	10/20/2011	12/15/2012
KDIAK.008EP	FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES	EP	Published	14841835.3	3/29/2016			3041513	7/13/2016	
KDIAK.008JP	FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES	JP	Published	2016-540916	3/8/2016			2016-530302	9/29/2016	
KDIAK.008NP	FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES	US	Published	14/916180	3/2/2016			2016/0199501 A1	7/14/2016	
KDIAK.009AU	DUAL PDGF/VEGF ANTAGONISTS	AU	Pending	2015279560	12/23/2016					
KDIAK.009CL	DUAL PDGF/VEGF ANTAGONISTS	US	Published	14/753824	6/29/2015			2015/0376271 A1	12/31/2015	
KDIAK.009CA	DUAL PDGF/VEGF ANTAGONISTS	CA	Pending	2953698	12/23/2016					
KDIAK.009CN	DUAL PDGF/VEGF ANTAGONISTS	CN	Pending	201580046779.3	2/28/2017					
KDIAK.009EP	DUAL PDGF/VEGF ANTAGONISTS	EP	Published	15812238.2	1/18/2017			3161000	5/3/2017	
KDIAK.009JP	DUAL PDGF/VEGF ANTAGONISTS	JP	Pending	2016-575823	12/28/2016					
KDIAK.009MX	DUAL PDGF/VEGF ANTAGONISTS	MX	Pending	MX/a/2016/017290	12/20/2016					
KDIAK.009ZA	DUAL PDGF/VEGF ANTAGONISTS	ZA	Pending	2016/08849	12/21/2016					

Kodiak Sciences - Patent Status Report

8/3/2017

Case No.	Title of Invention:	Country:	Status:	Application No.	Filing Date:	Patent No:	Date Issued:	PubNumber:	PubDate:	Expiration Date:
KDIAK.010CL	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	US	Published	14/932913	11/4/2015			2016/0184445 A1	6/30/2016	
KDIAK.010CN	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	CN	Pending	201580056449.2	4/17/2017					
KDIAK.010EP	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	EP	Pending	15851363	5/16/2017					
KDIAK.010JP	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	JP	Pending	2017-520515	4/14/2017					
KDIAK.010KR	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	KR	Pending	10-2017-7013268	5/17/2017					
KDIAK.010WO	BUTYRYLCHOLINESTER ASE ZWITTERIONIC POLYMER CONJUGATES	WO	Published	PCT/US2015/056112	10/16/2015			WO 2016/061562	4/21/2016	6/17/2017